Axovant Sciences today announced that the Phase 3 MINDSET trial of its Alzheimer’s drug intepirdine has failed to bring meaningful improvements in cognition or daily functioning.
from Dementia Big http://ift.tt/2wjL70y via alcoholic dementia
http://ift.tt/2k2jSWA
No comments:
Post a Comment